Overview
- Results published Tuesday in Nature Medicine showed the add-on drug cut the risk of death by 38% and doubled one-year survival.
- The randomized phase 2 trial, funded by Actuate Therapeutics, enrolled 233 untreated patients with metastatic pancreatic ductal adenocarcinoma across about 60 sites in six countries.
- Median overall survival reached 10.1 months with elraglusib plus chemotherapy, compared with 7.2 months on chemotherapy alone.
- Elraglusib targets GSK-3 beta and appears to rework the tumor’s surroundings to boost cancer-fighting immune cells inside tumors.
- The drug remains unapproved for routine care, with investigators aiming to launch a larger phase 3 study to confirm the benefit.